Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

Teerlink, John; Diaz, Rafael; Felker, G.; Mcmurray, John; Metra, Marco; Solomon, Scott; Adams, Kirkwood; Anand, Inder; Arias-Mendoza, Alexandra; Biering-Sorensen, Tor; Bohm, Michael; Bonderman, Diana; Cleland, John; Corbalan, Ramon; Crespo-Leiro, Maria; Dahlstrom, Ulf; Echeverria, Luis; Fang, James; Filippatos, Gerasimos; Fonseca, Candida; Goncalvesova, Eva; Goudev, Assen; Howlett, Jonathan; Lanfear, David; Li, Jing; Lund, Mayanna; Macdonald, Peter; Mareev, Viacheslav; Momomura, Shin-İchi; O'meara, Eileen; Parkhomenko, Alexander; Ponikowski, Piotr; Ramires, Felix; Serpytis, Pranas; Sliwa, Karen; Spinar, Jindrich; Suter, Thomas; Tomcsanyi, Janos; Vandekerckhove, Hans; Vinereanu, Dragos; Voors, Adriaan; Yılmaz, MEHMET; Zannad, Faiez; Sharpsten, Lucie; Legg, Jason; Varin, Claire; Honarpour, Narimon; Abbasi, Siddique; Malik, Fady; Kurtz, Christopher

doi:10.1056/nejmoa2025797

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

Teerlink J. R., Diaz R., Felker G. M., Mcmurray J. J. V., Metra M., Solomon S. D., ...More

NEW ENGLAND JOURNAL OF MEDICINE, vol.384, no.2, pp.105-116, 2021 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 384 Issue: 2
Publication Date: 2021
Doi Number: 10.1056/nejmoa2025797
Journal Name: NEW ENGLAND JOURNAL OF MEDICINE
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
Page Numbers: pp.105-116
Dokuz Eylül University Affiliated: Yes

Abstract

Among patients with heart failure and a reduced ejection fraction, those who received the cardiac myosin activator omecamtiv mecarbil had a lower incidence of a composite of heart-failure events or cardiovascular death at a median of 22 months than those who received placebo.